Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Orphan Drug Designation Approved for Everolimus, Tafamidis Meglumine
December 6, 2011
- Premium for New Drug Development to Be Continued on Trial Basis: CSIMC Expert Subcommittee
December 6, 2011
- 2010 Survey Shows Rise in Numbers of OB/GYN Doctors, Surgeons
December 6, 2011
- Takeda’s Novel ARB Azilva Recommended for Approval: PAFSC First Committee
December 5, 2011
- CSIMC General Assembly Points Out Some “Reckless” Evaluations on Policy Screening Report
December 5, 2011
- 80% Rule for Combination Drugs Will Be Applied to Injectables, Topical Drugs: MHLW Proposal
December 5, 2011
- MHLW Announces Results of Reexamination for Iressa, Remicade as Category I
December 5, 2011
- PAFSC 2nd Committee Recommends Designation of Thalidomide, Imatinib Mesylate as Orphan Drugs
December 5, 2011
- Decision on Price Freeze for Medically Essential Drugs to Be Postponed
December 5, 2011
- Expert Subcommittee Approves 60% Pricing Rule for Some New Generics Only
December 5, 2011
- NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 5, 2011
- NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 3, 2011
- Two New Drugs Including Ranmark from Daiichi Sankyo Recommended at PAFSC's 2nd Committee
December 2, 2011
- SS Council Committees Approve Basic Plan on FY2012 Medical Fee Revision
December 2, 2011
- Average Discrepancy Rate Remains at Approximately 8.4%: MHLW Flash Report
December 2, 2011
- Discussion Items for Upcoming Reform of NHI Drug Pricing System (Expert Subcommittee on NHI Drug Pricing Affairs, Dec. 2)
December 2, 2011
- CSIMC Approves Outline of Plan to Promote Generic Drug Use
December 1, 2011
- MHLW Announces Revision of Precautions for Anastrozole, Temozolomide
December 1, 2011
- CSIMC Expert Member Yoshimura Says Conditions Must Improve to Promote Generics
November 30, 2011
- Gov’t to Decide on Extension of Urgent Vaccination Project “as Soon as Possible”
November 30, 2011
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…